Proton Pump Inhibitor Selection in Hepatic Impairment
Pantoprazole is preferred for use in hepatic impairment because no dosage adjustment is required in patients with mild to severe hepatic impairment (Child-Pugh A to C). [1] Omeprazole requires dosage reduction for maintenance of healing of erosive esophagitis in patients with hepatic impairment (Child-Pugh A to C). [2]
Medication Selection Algorithm
- Preferred: Pantoprazole (no dosage adjustment required in mild to severe hepatic impairment). [1]
- Alternative: Omeprazole (dose reduction to 10 mg once daily recommended for maintenance of healing of erosive esophagitis in hepatic impairment). [2]
Key Evidence Supporting This Recommendation
- Pantoprazole pharmacokinetics in mild to severe hepatic impairment (Child-Pugh A to C) showed only slight increases in maximum concentrations and minimal drug accumulation with once-daily dosing. [1]
- Omeprazole exposure substantially increases in hepatic impairment and a reduced dose is recommended for maintenance of healing of erosive esophagitis. [2]
Monotherapy vs Combination Therapy Considerations
- No PPI combination is required for hepatic impairment dosing selection. [1][2]
- Acid-suppression goals should be managed by selecting a PPI with appropriate hepatic dosing rather than adding another PPI. [1][2]
Initiation Thresholds and Indications
- Pantoprazole may be initiated at standard dosing in mild to severe hepatic impairment (Child-Pugh A to C) without dosage adjustment. [1]
- Omeprazole should use a reduced dose when indicated for maintenance of healing of erosive esophagitis in hepatic impairment (Child-Pugh A to C). [2]
Common Pitfalls to Avoid
- Using omeprazole at maintenance dosing without applying the hepatic impairment dose reduction recommendation increases exposure in hepatic impairment. [2]
- Assuming that “hepatic impairment” is managed the same way for all PPIs. [1][2]